Milton Wainberg1, Lisa Dixon2. 1. Columbia University Medical Center, New York State Psychiatric Institute, New York, NY 10032, USA. 2. Columbia University Medical Center, New York State Psychiatric Institute, New York, NY 10032, USA. Electronic address: lisa.dixon@nyspi.columbia.edu.
HIV, hepatitis B (HBV), and hepatitis C (HCV) are preventable serious blood-borne
infections. Early detection and accessible and user-friendly treatments improve
prognosis, cure (for HCV), and prevent further transmission. 30 years of previous
studies in a range of population samples have suggested that severe mental illness is a
risk factor for contracting blood-borne viruses (BBVs).[1] In The Lancet Psychiatry,
Clarissa Bauer-Staeb and colleagues[2]
confirm the elevated risk for BBVs experienced by individuals with severe mental illness
in a total population study of Sweden, finding that the odds of HIV were 2·57
(95% CI 2·25–2·94, p<0·0001) times higher in people
with severe mental illness than in the general population, whereas the odds of HBV were
2·29 (2·09–2·51, p<0·0001) times higher and
the odds of HCV were 6·18 (5·98–6·39,
p<0·0001) times higher. This result increases confidence in the validity
of previous studies with more narrowly selected samples.After the first case of HIV infection among people with severe mental illness was
identified in 1983,[3] multiple studies
worldwide have reported high prevalence of HIV infection among people with severe mental
illness.[1] Since then,
pioneering research in the USA with people with severe mental illness has shown positive
effects on a range of outcomes including measures of condom use, HIV knowledge, and
sexual behaviours[4]—yet the
epidemic among people with severe mental illness continues to be inadequately addressed.
High prevalence of HBV and HCV are also well known and are similarly
unaddressed.[1] Over the past 5
years, the increasingly well established disparities in the physical health of people
with severe mental illness have become health policy priorities; however, these policies
do not target sexual health and risk factors facilitating transmission of
BBVs.[1]Transmission of BBVs occur through unprotected anal, vaginal, or oral sex;
through mother to child vertical transmission; by sharing drug-injecting paraphernalia;
and parenterally with contaminated blood and blood products or contaminated instruments
and needles. In some circumstances, people with severe mental illness might be more
vulnerable to engaging in behaviours that increase their risk of infection with BBVs,
including unprotected sex, sex in exchange for a commodity (eg, money, shelter, food),
and sharing equipment for intravenous drug use. Ending the HIV epidemic requires routine
testing for HIV infection; prevention of infection among HIV-negative individuals with
effective risk-reduction interventions and prescriptions of pre-exposure prophylaxis;
and antiretroviral treatment for individuals who are HIV-positive until viral
suppression is accomplished (treatment as prevention) to decrease forward
transmission.[5] A vaccine
against HBV confers greater than 95% immunity in three doses.[6] Screening for HCV followed by treatment can cure
infection in more than 95% of patients.[7] One question raised by Bauer-Staeb and colleagues’
Article[2] is whether individuals
with a diagnosis of severe mental illness have as much access to these interventions as
do people without severe mental illness.Education alone does not confer prevention. Routine HIV, HBV, or HCV testing has
not been implemented in most mental health settings. Efficacious HIV and HCV
risk-reduction interventions are available; however, they are either not offered in
psychiatric settings or, when they are, they are offered only to those known to be
HIV-infected or who self-disclose risky sexual behaviour. People whose risks are not so
obvious are easily overlooked. Similarly, HBV vaccination and HCV treatment are seldom
available in mental health-care settings. The inaccurate assumption made by some mental
health providers that people with severe mental illness do not engage in intravenous
drug use or unprotected sex can result in patients not receiving proper care.[1,8]Psychiatric facilities are perfect settings for implementation of testing,
prevention, and treatment of BBVs tailored to individuals with severe mental
illness.[9] Caring and supportive
providers already engaged in therapeutic relationships with their patients can address
barriers, alleviate concerns, and facilitate comprehensive prevention and care. Barriers
to provision of prevention, testing, and care to people with severe mental illness
include insufficient training of mental health staff in evidence-based interventions;
inadequate funds, including little money for condoms; the separation of psychiatric and
medical services; and providers’ failure to address patients’ romantic
partnerships, sexual needs, and psychotropic medication side-effects.[9]Global efforts to end HIV, HBV, and HCV as a public health threats are underway,
but the extent to which public psychiatric care systems are participating is unknown
despite evidence that individuals with severe mental illness have higher prevalence of
BBVs than those in the general population. Recovery guidelines include integration of
physical health and mental health care,[10,11] but uptake of
prevention and intervention strategies for HIV, HBV, and HCV has been scarce in
real-world mental health settings.[12]
People with severe mental illness must be specifically included in current well funded
global initiatives to reduce transmission of BBVs and achieve the goal of ending the
HIV, HBV, and HCV epidemics.[5] This goal
requires a greater commitment from governments and public mental health-care systems to
systematically and comprehensively reach this disproportionally affected population.
Authors: Milton L Wainberg; M Alfredo González; Karen McKinnon; Katherine S Elkington; Diana Pinto; Claudio Gruber Mann; Paulo E Mattos Journal: Soc Sci Med Date: 2007-05-01 Impact factor: 4.634
Authors: Peter Piot; Salim S Abdool Karim; Robert Hecht; Helena Legido-Quigley; Kent Buse; John Stover; Stephen Resch; Theresa Ryckman; Sigrun Møgedal; Mark Dybul; Eric Goosby; Charlotte Watts; Nduku Kilonzo; Joanne McManus; Michel Sidibé Journal: Lancet Date: 2015-06-24 Impact factor: 79.321
Authors: Baligh R Yehia; Wanjun Cui; William W Thompson; Matthew M Zack; Lela McKnight-Eily; Elizabeth DiNenno; Charles E Rose; Michael B Blank Journal: AIDS Patient Care STDS Date: 2014-12 Impact factor: 5.078
Authors: Karen L Whiteman; John A Naslund; Elizabeth A DiNapoli; Martha L Bruce; Stephen J Bartels Journal: Psychiatr Serv Date: 2016-06-15 Impact factor: 3.084
Authors: F Cournos; M Empfield; E Horwath; K McKinnon; I Meyer; H Schrage; C Currie; B Agosin Journal: Am J Psychiatry Date: 1991-09 Impact factor: 18.112
Authors: Vikram Patel; Ricardo Araya; Sudipto Chatterjee; Dan Chisholm; Alex Cohen; Mary De Silva; Clemens Hosman; Hugh McGuire; Graciela Rojas; Mark van Ommeren Journal: Lancet Date: 2007-09-15 Impact factor: 79.321
Authors: Abdullah Pandor; Eva Kaltenthaler; Agnes Higgins; Karen Lorimer; Shubulade Smith; Kevan Wylie; Ruth Wong Journal: BMC Public Health Date: 2015-02-12 Impact factor: 3.295
Authors: Clarissa Bauer-Staeb; Lena Jörgensen; Glyn Lewis; Christina Dalman; David P J Osborn; Joseph F Hayes Journal: Lancet Psychiatry Date: 2017-07-04 Impact factor: 27.083